During the recent session, Lyra Therapeutics Inc (NASDAQ:LYRA)’s traded shares were 0.44 million, with the beta value of the company hitting -0.13. The 52-week high for the LYRA share is $6.79, that puts it down -3473.68 from that peak though still a striking 15.79% gain since the share price plummeted to a 52-week low of $0.16. The company’s market capitalization is $12.75M, and the average intraday trading volume over the past 10 days was 1.13 million shares, and the average trade volume was 2.02 million shares over the past three months.
Lyra Therapeutics Inc (LYRA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. LYRA has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Lyra Therapeutics Inc (LYRA) registered a 1.09% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.09% in intraday trading to $0.19, hitting a weekly high. The stock’s 5-day price performance is 3.02%, and it has moved by 14.53% in 30 days. Based on these gigs, the overall price performance for the year is -96.11%. The short interest in Lyra Therapeutics Inc (NASDAQ:LYRA) is 2.1 million shares and it means that shorts have 1.24 day(s) to cover.
The consensus price target of analysts on Wall Street is $0.5, which implies an increase of 62.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $0.5 and $0.5 respectively. As a result, LYRA is trading at a discount of -163.16% off the target high and -163.16% off the low.
Lyra Therapeutics Inc (LYRA) estimates and forecasts
Statistics show that Lyra Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Lyra Therapeutics Inc (LYRA) shares have gone down -35.08% during the last six months, with a year-to-date growth rate less than the industry average at -12.20% against 16.90.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -21.63%. While earnings are projected to return -5.36% in 2025.
LYRA Dividends
Lyra Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Lyra Therapeutics Inc (NASDAQ:LYRA)’s Major holders
Lyra Therapeutics Inc insiders own 0.60% of total outstanding shares while institutional holders control 59.72%, with the float percentage being 60.08%. PERCEPTIVE ADVISORS LLC is the largest shareholder of the company, while 81.0 institutions own stock in it. As of 2024-06-30, the company held over 12.76 million shares (or 19.9302% of all shares), a total value of $3.53 million in shares.
The next largest institutional holding, with 4.77 million shares, is of CITADEL ADVISORS LLC’s that is approximately 7.4562% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.32 million.
Also, the Mutual Funds coming in first place with the largest holdings of Lyra Therapeutics Inc (LYRA) shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. Data provided on Oct 31, 2024 indicates that iShares Russell 2000 ETF owns about 2.32 shares. This amounts to just over 3.55 percent of the company’s overall shares, with a $0.45 million market value. The same data shows that the other fund manager holds slightly less at 992.54, or about 1.52% of the stock, which is worth about $0.19 million.
